Radiology’s Challenges for Stage 2 of Meaningful Use
In this video interview, the ACR’s Michael Peters explains what’s new in Stage 2 of meaningful use, the challenges radiologists face and how to stay informed.
In Stage 2 of the federal meaningful use program, providers were given much more flexibility in the technology they adopt to comply. It’s not just electronic health records (EHRs) that qualify, but a far broader term: certified electronic health records. This is welcome news for physicians, like radiologists, who use specialized health IT products, said Michael Peters, director of legislative and regulatory affairs for the American College of Radiology.
In this video interview, Peters explains this change for Stage 2. He also details the greatest challenges for radiologists in achieving meaningful use, the significant hardship exemption, and the need for providers to learn as much as they can about the program.
“I would encourage radiologist whenever possible to seek credible sources,” he said. “There’s a lot of good information available to folks if they’re willing to look for it.”
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
